Європейський Союз - словацька - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anémia, kosáčiková bunka - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

boston scientific neuromodulation corporation 25155 rye canyon loop valencia, ca spojené štáty americké -

Європейський Союз - словацька - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - ošípané - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

siemens healthcare gmbh henkestrasse 127 de-91052 erlangen nemecko -

Європейський Союз - словацька - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

alpha omega engineering ltd. hamerkava st. 6 1789 062 nof hagalil (nazareth illit) izrael -

Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

alpha omega engineering ltd. hamerkava st. 6 1789 062 nof hagalil (nazareth illit) izrael -

Словаччина - словацька - ŠÚKL (Štátny ústav pre kontrolu liečiv)

alpha omega engineering ltd. hamerkava st. 6 1789 062 nof hagalil (nazareth illit) izrael -

Європейський Союз - словацька - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Європейський Союз - словацька - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabryho choroba - iné alimentárny trakt a metabolizmus výrobky, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).